Publications by authors named "M Morris"

4,765 Publications

  • Page 1 of 1

The politics of testing positive: an autoethnography of media (mis)representations at the 'start' and 'end' of different pandemics.

Authors:
Max Morris

Cult Health Sex 2021 Jun 11:1-15. Epub 2021 Jun 11.

Department of Criminology and Sociology, Kingston University, Kingston-Upon-Thames, UK.

This paper draws on an autoethnographic 'digital diary' which the author began after testing positive for HIV in July 2016, until May 2021, to critically assess (mis)representations of both the AIDS and COVID-19 pandemics in the media. Drawing on insights from art, literature, queer theory and social anthropology, the paper focuses on dominant moral and political discourses to show how narratives of blame, shame and guilt about viral transmission contribute to the stigmatisation of 'at risk' groups. Concepts of biopower and normative judgement are used to reflect on discourses which construct those who 'test positive' for HIV or SARS-CoV-2 as 'reckless', 'risky' or 'irresponsible' subjects. The paper also analyses notes on recent media appearances made by the author to discuss their participation in the PARTNER study, which showed that HIV antiretroviral therapy eliminates the possibility of HIV transmission, including reports in , on , , on , and in the . As the former had reported that the 'Covid-19 crisis raises hopes of end to UK transmission of HIV', portrayals of the two pandemics are compared to explore tensions between public health and individual responsibility as normative priorities.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1080/13691058.2021.1930172DOI Listing
June 2021

Development of a Coronavirus Disease 2019 (COVID-19) Application Ontology for the Accrual to Clinical Trials (ACT) network.

JAMIA Open 2021 Apr 19;4(2):ooab036. Epub 2021 Apr 19.

Clinical and Translational Science Institute, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.

Clinical data networks that leverage large volumes of data in electronic health records (EHRs) are significant resources for research on coronavirus disease 2019 (COVID-19). Data harmonization is a key challenge in seamless use of multisite EHRs for COVID-19 research. We developed a COVID-19 application ontology in the national Accrual to Clinical Trials (ACT) network that enables harmonization of data elements that are critical to COVID-19 research. The ontology contains over 50 000 concepts in the domains of diagnosis, procedures, medications, and laboratory tests. In particular, it has computational phenotypes to characterize the course of illness and outcomes, derived terms, and harmonized value sets for severe acute respiratory syndrome coronavirus 2 laboratory tests. The ontology was deployed and validated on the ACT COVID-19 network that consists of 9 academic health centers with data on 14.5M patients. This ontology, which is freely available to the entire research community on GitHub at https://github.com/shyamvis/ACT-COVID-Ontology, will be useful for harmonizing EHRs for COVID-19 research beyond the ACT network.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1093/jamiaopen/ooab036DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8083220PMC
April 2021

When mentoring matters: a French mentoring program for women in science.

Nat Biotechnol 2021 Jun;39(6):776-779

Institut des Biomolécules Max Mousseron, CNRS-UMR 5247, University of Montpellier, Montpellier, France.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41587-021-00951-2DOI Listing
June 2021

A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer.

Clin Cancer Res 2021 Jun 9. Epub 2021 Jun 9.

Prostate and Urologic Cancers Program, Yale Cancer Center.

Purpose: Men with metastatic castration-resistant prostate cancer (mCRPC) have limited treatment options after progressing on hormonal therapy and chemotherapy. Here, we evaluate the safety and efficacy of atezolizumab (anti-PD-L1) + radium-223 dichloride in men with mCRPC.

Experimental Design: This phase Ib study evaluated atezolizumab + radium-223 in men with mCRPC and bone and lymph node and/or visceral metastases that progressed after androgen pathway inhibitor treatment. Following safety assessment of concurrent dosing, 45 men were randomized 1:1:1 to concurrent or one of two staggered dosing schedules with either agent introduced one cycle before the other. This was followed by a safety-efficacy expansion cohort (randomized 1:1:1). The primary endpoints were safety and objective response rate (ORR) by RECIST 1.1. Secondary endpoints included radiographic progression-free survival (rPFS), prostate-specific antigen (PSA) responses and overall survival (OS).

Results: As of October 4, 2019, 44 of 45 men were evaluable. All 44 had {greater than or equal to}1 all-cause adverse event (AE); 23 (52.3%) had a grade 3/4 AE. Fifteen (34.1%) grade 3/4 and 3 (6.8%) grade 5 AEs were related to atezolizumab; none were related to radium-223. Confirmed ORR was 6.8% (95% CI: 1.4-18.7), median rPFS was 3.0 months (95% CI: 2.8-4.6), median PSA progression was 3.0 months (95% CI: 2.8-3.3) and median OS was 16.3 months (95% CI: 10.9-22.3).

Conclusions: This phase Ib study demonstrated that atezolizumab+radium-223, regardless of administration schedule, had greater toxicity than either drug alone, with no clear evidence of additional clinical benefit for patients with mCRPC and bone and lymph node and/or visceral metastases.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-21-0063DOI Listing
June 2021

In Reply to Langley et al.

Int J Radiat Oncol Biol Phys 2021 Jul;110(3):913-914

Department of Health Services Research and Policy, LSHTM, London, England; Department of Radiotherapy, Guy's and St Thomas' NHS Foundation Trust, London, England.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2021.02.037DOI Listing
July 2021